93 completed, 30 unknown, 15 terminated, 13 recruiting. 48 Phase 3, 46 Phase 4, 35 Phase 2, 23 Not applicable, 8 Phase 1.
Follow Ceftriaxone: new trials by email Literature Review of Ceftriaxone trials Research Report on Ceftriaxone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Piperacillin/Tazobactam Versus Ceftriaxone and Metronidazole for Children With Perforated Appendicitis Piperacillin/Tazobactam, Ceftriaxone + Metronidazole - Appendicitis Perforated, Appendectomy, Laparoscopic | Phase 3 | Not yet recruiting | McMaster Children's Hospital | 180 | 2027-04-01 | 2026-10-09 |
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| All-Oral Fluoroquinolone-Based Triple Therapies for Adults With Imaging-Confirmed Osteoarticular Brucellosis Doxycycline + Rifampicin + Ceftriaxone (intravenous therapy for 4 weeks), Triple oral regimen (Doxycycline + Rifampicin + Levofloxacin), Triple oral regimen (Doxycycline + Rifampicin + Moxifloxacin) - Brucellosis, Osteoarticular Brucellosis | Not applicable | Not yet recruiting | The First Affiliated Hospital of Shihezi University | 150 | 2026-11-01 | 2026-10-21 |
| AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth Vaginal flora abnormalities screening and quantification using molecular biology technique, Azithromycin, Ceftriaxone - Bacterial Vaginosis, Vaginal Dysbiosis | Phase 3 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 1794 | 2026-10-01 | 2026-08-27 |
| Efficacy & Safety of Fluoroquinolone-Based Brucellosis Regimens (BRUCE) Doxycycline + Rifampicin, Doxycycline + Levofloxacin, Doxycycline + Moxifloxacin - Brucellosis, Osteoarthritis | Not applicable | Withdrawn | The First Affiliated Hospital of Shihezi University | 2026-10-01 | 2026-10-27 | |
| Efficacy of Temocillin Compared to Standard of Care in the Treatment of Neisseria Gonorrhoeae Infections Temocillin (NEGABAN®) 2 g intravenous with lidocaine (3ml), Rectal swab for ESBL-E and microbiota (Eswab), Temocillin (NEGABAN®) 2 g intramuscular single dose with lidocaine (3ml) - Neisseria Gonorrhoeae (Ng) Infections | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 360 | 2026-09-01 | 2026-06-22 |
| A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor Combination of antibiotics, Emergency cerclage, Vaginal progesterone - Previable Labour With Intact Membranes | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 350 | 2026-09-01 | 2026-05-01 |
| 500-mg Versus 1000-mg Ceftriaxone for Uncomplicated Gonorrhea Infection ceftriaxone 500-mg, ceftriaxone 1000-mg - Gonorrhea Infection | Phase 3 | Recruiting | National Taiwan University Hospital | 400 | 2026-07-01 | 2026-07-17 |
| Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy Ceftriaxon, Benzathine penicillin G - Pregnancy | Recruiting | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | 110 | 2026-02-16 | 2026-08-06 | |
| PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury Ceftriaxone 2g diluted in >200ml 0.9%sodium chloride, Placebo comparator - no ceftriaxone - All-cause Mortality, Quality of Life | Phase 3 | Recruiting | The George Institute | 3300 | 2025-10-30 | 2026-08-28 |
| Risk Factors of Failure of Conservative Treatment in Acute Non Complicated Appendicitis ceftriaxone, ceftriaxone 1 gm/12 hourly and IV metronidazole 500 mg/8 hourly - Conservative Management | Not yet recruiting | Ahmed Mohammed Hussein Sayed | 100 | 2025-06-22 | 2025-02-17 | |
| Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients ROCEPHIN, metronidazole, RIFADIN, IZILOX, placebo combination therapy, Lymecyclin and corresponding placebos of the experimental arm - Hidradenitis Suppurativa | Phase 3 | Recruiting | Institut Pasteur | 92 | 2025-05-22 | 2025-07-09 |
| Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge - Drug Allergy, Cephalosporin Allergy | Phase 2 | Recruiting | Massachusetts General Hospital | 300 | 2025-05-05 | 2026-11-12 |
| Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease Ceftriaxone (Rocephin®), Dextrose 5% (D5W) - Post-Treatment Lyme Disease | Early Phase 1 | Recruiting | State University of New York - Upstate Medical University | 44 | 2025-02-03 | 2026-03-19 |
| Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis. Ampicillin plus ceftriaxone in continuous infusion, Ampicillin plus ceftriaxone in intermittent infusion of 14 days, after which the treatment may be changed - Endocarditis, Infective | Phase 4 | Recruiting | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 284 | 2024-10-09 | 2025-07-25 |
| Comparison of Efficacy of Oral Amoxicillin Versus Intravenous Ceftriaxone Amoxicillin/CA, IV ceftriaxone - Community-acquired Pneumonia | Not applicable | Unknown | RESnTEC, Institute of Research | 114 | 2024-10-01 | 2024-08-01 |
| Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA) Piperacillin/tazobactam, Normal saline, CefTRIAXone Injection - Appendicitis Perforated | Phase 2 | Completed | McMaster Children's Hospital | 16 | 2024-09-09 | 2026-07-07 |
| Enhanced Molecular Microbiological Surveillance Versus Ceftriaxone Prophylaxis in Hematopoietic Cell Transplant Patients Ceftriaxone 1000 MG - Incidence of Infectious Diseases | Not applicable | Recruiting | Pomeranian Medical University Szczecin | 100 | 2024-09-01 | 2025-12-29 |
| Prophylactic Antibiotic in Subtalar Fusion Surgery Ceftriaxone 2000 mg - Surgical Site Infection | Phase 2 / Phase 3 | Unknown | Assiut University | 102 | 2024-09-01 | 2024-07-30 |
| Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin - Community Acquired Pneumonia in Children | Phase 4 | Recruiting | Medical College of Wisconsin | 236 | 2024-08-22 | 2026-03-02 |
Showing 20 of 162. Sign in to see all of them.
Gonorrhea (15) · Infections (15) · Pneumonia (15) · Community-Acquired Pneumonia (13) · Sepsis (10) · Appendicitis (8) · Bacterial Infections (6) · Lyme Neuroborreliosis (6) · Lyme Disease (5) · Pneumonia, Bacterial (5) · Shock, Septic (5) · Surgical Wound Infection (5) · Urinary Tract Infections (5) · Critical Illness (4) · Pneumonia, Ventilator-Associated (4)
Assistance Publique - Hôpitaux de Paris (6) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Forest Laboratories (5) · Pfizer (4) · University Medical Centre Ljubljana (4) · Bayer (3) · Melinta Therapeutics, Inc. (3) · University of Oxford (3) · Beijing Children's Hospital (2) · Centre Hospitalier Universitaire de Besancon (2) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (2) · Haiphong University of Medicine and Pharmacy (2) · Harold Wiesenfeld (2) · Makerere University (2) · Massachusetts General Hospital (2)
United States (53) · France (20) · Spain (15) · Canada (13) · Australia (10) · Taiwan (10) · China (8) · India (8) · Argentina (7) · Belgium (7) · Germany (7) · Hungary (7) · Poland (7) · Ukraine (7) · Netherlands (6)
A-Dong Shen, Master (2) · Franc Strle, MD (2) · A.K. Deb (1) · Ahmad Zia Ud Din (1) · Alina Tone, MD (1) · Allison R Lauver, PharmD (1) · Ambrose Agweyu, PhD (1) · Amos O Adeleye, FWACS, FACS (1) · Andrew Udy, Prof (1) · Anita KM Zaidi, MBBS, SM (1) · Anthony Delaney, Prof (1)
PMID 26702925, PMID 30597021, PMID 34922058, PMID 21482570, PMID 23357290, PMID 25487791, PMID 1444289, PMID 1482149, PMID 15276398, PMID 15557948, PMID 15840453, PMID 16304153, PMID 16531428, PMID 16640454, PMID 16948498, PMID 17135183, PMID 17509029, PMID 17611232, PMID 17696583, PMID 17846133, PMID 18061594, PMID 18419482, PMID 18462108, PMID 18567539, PMID 18762516, PMID 18788687, PMID 19095679, PMID 19237886, PMID 19238021, PMID 19286178, PMID 19398460, PMID 19588358, PMID 19947907, PMID 20561826, PMID 20670293, PMID 20927758, PMID 20949884, PMID 21129208, PMID 21142293, PMID 21482566, PMID 21482568, PMID 21545483, PMID 21692712, PMID 21730935, PMID 21788467, PMID 21829969, PMID 21835401, PMID 21862409, PMID 2209498, PMID 22112612
2023 (3), U19AI084024 (2), 2008 (1), 2014 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2025 (1), P20GM139745 (1), U01AI162457 (1), U01AI184071 (1), U01NS049640 (1), UM1AI068616 (1), UM1AI068632 (1)